• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现一种有效、选择性和共价的 ZAP-70 激酶抑制剂。

Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.

机构信息

Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, #555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Science, 19 Yuquan Road, Beijing, 110039, China.

Laboratory of Anti-inflammation and Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.

出版信息

Eur J Med Chem. 2021 Jul 5;219:113393. doi: 10.1016/j.ejmech.2021.113393. Epub 2021 Mar 30.

DOI:10.1016/j.ejmech.2021.113393
PMID:33845236
Abstract

ZAP-70 (zeta-chain associated protein kinase 70 kDa) signaling pathway and its functions have been involved in the development and adaptive immune signaling of T cell. It thus represents a promising target for autoimmune diseases. Although reversible ZAP-70 kinase domain inhibitors have been developed, they are either weak or nonselective. We report herein the structure-guided development of the first potent and covalent inhibitor of ZAP-70 kinase domain. In particular, compound 18 (RDN009) showed good selectivity for ZAP-70 over structurally related Syk, and displayed potent inhibitory effects on T cell proliferation, activation, and inflammatory cytokine production. A mass spectrometry analysis further confirmed the covalent linkage between the inhibitor and ZAP-70 protein at C346. Overall, the covalent inhibitor RDN009 represents a potent and selective probe of ZAP-70 for further development for treatment of autoimmune diseases.

摘要

ZAP-70(zeta 链相关蛋白激酶 70 kDa)信号通路及其功能已涉及 T 细胞的发育和适应性免疫信号转导。因此,它是自身免疫性疾病的一个很有前途的靶点。尽管已经开发出了可逆的 ZAP-70 激酶结构域抑制剂,但它们要么作用较弱,要么选择性不强。我们在此报告了基于结构的 ZAP-70 激酶结构域的首个强效和共价抑制剂的开发。特别是,化合物 18(RDN009)对 ZAP-70 具有良好的选择性,相对于结构相关的 Syk 激酶,显示出对 T 细胞增殖、活化和炎症细胞因子产生的有效抑制作用。质谱分析进一步证实了抑制剂与 ZAP-70 蛋白在 C346 位的共价结合。总的来说,共价抑制剂 RDN009 是 ZAP-70 的一种有效且选择性的探针,可进一步开发用于治疗自身免疫性疾病。

相似文献

1
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.发现一种有效、选择性和共价的 ZAP-70 激酶抑制剂。
Eur J Med Chem. 2021 Jul 5;219:113393. doi: 10.1016/j.ejmech.2021.113393. Epub 2021 Mar 30.
2
Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.5-苄基氨基咪唑并[1,2-c]嘧啶-8-甲酰胺衍生物作为强效、高选择性ZAP-70激酶抑制剂的构效关系研究
Bioorg Med Chem. 2009 Jan 1;17(1):284-94. doi: 10.1016/j.bmc.2008.10.070. Epub 2008 Nov 5.
3
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.通过对接至Syk罕见的C螺旋向外构象发现双ZAP70和Syk激酶抑制剂。
Bioorg Med Chem Lett. 2014 Mar 15;24(6):1523-7. doi: 10.1016/j.bmcl.2014.01.083. Epub 2014 Feb 10.
4
Discovery of ZAP70 inhibitors by high-throughput docking into a conformation of its kinase domain generated by molecular dynamics.通过高通量对接分子动力学生成的激酶结构域构象发现 ZAP70 抑制剂。
Bioorg Med Chem Lett. 2013 Oct 15;23(20):5721-6. doi: 10.1016/j.bmcl.2013.08.009. Epub 2013 Aug 11.
5
Designing of new multi-targeted inhibitors of spleen tyrosine kinase (Syk) and zeta-associated protein of 70kDa (ZAP-70) using hierarchical virtual screening protocol.采用层次虚拟筛选方案设计新型脾酪氨酸激酶(Syk)和zeta 相关蛋白 70kDa(ZAP-70)多靶点抑制剂。
J Mol Graph Model. 2013 Feb;39:165-75. doi: 10.1016/j.jmgm.2012.11.011. Epub 2012 Dec 8.
6
Discovery and Structural Optimization of Covalent ZAP-70 Kinase Inhibitors against Psoriasis.发现和结构优化针对银屑病的共价 ZAP-70 激酶抑制剂。
J Med Chem. 2023 Sep 14;66(17):12018-12032. doi: 10.1021/acs.jmedchem.3c00606. Epub 2023 Aug 18.
7
Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.咪唑并[1,2-c]嘧啶衍生物作为强效口服有效的Syk家族激酶抑制剂的构效关系研究
Bioorg Med Chem. 2008 Oct 15;16(20):9247-60. doi: 10.1016/j.bmc.2008.09.015. Epub 2008 Sep 9.
8
Discovery of new Syk inhibitors through structure-based virtual screening.通过基于结构的虚拟筛选发现新型脾酪氨酸激酶抑制剂
Bioorg Med Chem Lett. 2017 Apr 15;27(8):1776-1779. doi: 10.1016/j.bmcl.2017.02.060. Epub 2017 Feb 24.
9
Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis.发现新型 Syk/PDGFR-α/c-Kit 抑制剂作为治疗类风湿关节炎的多靶点药物。
Bioorg Med Chem. 2018 Aug 15;26(15):4375-4381. doi: 10.1016/j.bmc.2018.06.029. Epub 2018 Jun 22.
10
Inhibition of T Cell Receptor Activation by Semi-Synthetic Sesquiterpene Lactone Derivatives and Molecular Modeling of Their Interaction with Glutathione and Tyrosine Kinase ZAP-70.半合成倍半萜内酯衍生物对 T 细胞受体激活的抑制作用及其与谷胱甘肽和酪氨酸激酶 ZAP-70 相互作用的分子建模。
Molecules. 2019 Jan 19;24(2):350. doi: 10.3390/molecules24020350.

引用本文的文献

1
Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction.Janus激酶抑制剂的药效团模型:药物发现与暴露预测工具
Molecules. 2025 May 16;30(10):2183. doi: 10.3390/molecules30102183.
2
Autoimmune hypothyroidism GWAS reveals independent autoimmune and thyroid-specific contributions and an inverse relation with cancer risk.自身免疫性甲状腺功能减退症全基因组关联研究揭示了独立的自身免疫和甲状腺特异性作用以及与癌症风险的负相关关系。
Res Sq. 2024 Jul 8:rs.3.rs-4626646. doi: 10.21203/rs.3.rs-4626646/v1.
3
Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients.
类风湿关节炎患者减轻抗 TNF 生物制剂免疫原性的药物策略。
Curr Opin Pharmacol. 2023 Feb;68:102320. doi: 10.1016/j.coph.2022.102320. Epub 2022 Dec 27.
4
Expanding the Diversity at the C-4 Position of Pyrido[2,3-]pyrimidin-7(8)-ones to Achieve Biological Activity against ZAP-70.扩展吡啶并[2,3 - ]嘧啶 - 7(8) - 酮C - 4位的多样性以实现对ZAP - 70的生物活性。
Pharmaceuticals (Basel). 2021 Dec 15;14(12):1311. doi: 10.3390/ph14121311.